COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Cytokinetics
Information provided by (Responsible Party):
Amgen
ClinicalTrials.gov Identifier:
NCT01786512
First received: January 18, 2013
Last updated: April 3, 2015
Last verified: April 2015
  Purpose

The primary objectives of this study are (i) to select an oral modified release (MR) formulation and dose of omecamtiv mecarbil for chronic twice daily (BID) dosing in subjects with HF and left ventricular systolic dysfunction and (ii) to characterize its pharmacokinetics (PK) over 20 weeks of treatment.


Condition Intervention Phase
Modified Release Oral Formulation
Left Ventricular Systolic Dysfunction
Chronic Heart Failure
History of Chronic Heart Failure
Left Ventricular Ejection Fraction
Pharmacokinetics
Echocardiogram
Drug: Omecamtiv mecarbil
Drug: Placebo
Drug: Omecamtiv Mecarbil
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction

Resource links provided by NLM:


Further study details as provided by Amgen:

Primary Outcome Measures:
  • Dose Escalation - Characterize Pharmacokinetics - Cmax [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7 ] [ Designated as safety issue: Yes ]
    Maximum Observed Plasma Concentration (Cmax)

  • Dose Escalation - Characterize Pharmacokinetics -Cmin [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7 ] [ Designated as safety issue: Yes ]
    Minimum Observed Concentration (Cmin)

  • Dose Escalation - Characterize Pharmacokinetics-Tmax [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 96, 120 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 168 hours following dose on day 7 ] [ Designated as safety issue: Yes ]
    Time to Reach Maximum Plasma Concentration (Tmax)

  • Dose Escalation - Characterize Pharmacokinetics - AUC12h [ Time Frame: 0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours after first dose; 0, 0.5, 1, 2, 3, 4, 6, 8, 12 hours following dose on day 7 ] [ Designated as safety issue: Yes ]
    Area under the curve until 12 hours after investigational product (IP) administration (AUC12h)

  • Dose Expansion - Characterize Pharmacokinetics - Cmax [ Time Frame: predose, predose, 1 , 2, 4, 6, and 8 hours after morning dose on weeks 2 and 12; predose, between 1-4 hours post dose on week 20 ] [ Designated as safety issue: Yes ]
    Maximum Observed Plasma Concentration (Cmax)

  • Dose Expansion - Characterize Pharmacokinetics - Cpredose [ Time Frame: predose before morning dose on Day1, weeks 2, 8 , 12, 16 and 20 ] [ Designated as safety issue: Yes ]
    Concentration prior to IP administration (Cpredose)


Secondary Outcome Measures:
  • Systolic Ejection Time(SET) (msec) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    Changes from baseline in Systolic Ejection Time (SET)

  • Left Ventricular End-Systolic Diameter (LVESD) (cm) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    Changes from baseline in Left Ventricular End-Systolic Diameter (LVESD)

  • Left Ventricular End-Diastolic Diameter (LVEDD) (cm) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    Changes from baseline in Left Ventricular End-Diastolic Diameter (LVEDD)

  • Heart Rate (beats per minute) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    Changes from baseline in heart rate

  • Stroke Volume (ml) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    Changes from baseline in Stroke Volume

  • Effect of omecamtiv mecarbil on NT-proBNP (pg/mL) [ Time Frame: baseline and 20 weeks ] [ Designated as safety issue: No ]
    To evaluate the effect of 12 weeks of oral dosing with omecamtiv mecarbil on Nterminal pro-B-type natriuretic peptide (NT-proBNP)

  • Dose Escalation - Safety and tolerability of oral omecamtiv mecarbil [ Time Frame: baseline to 35 days ] [ Designated as safety issue: Yes ]
    Subject incidence of adverse events from baseline to 35 days (end of study)

  • Dose Expansion - Safety and tolerability of oral omecamtiv mecarbil [ Time Frame: baseline to 24 weeks ] [ Designated as safety issue: Yes ]
    Subject incidence of adverse events from baseline to week 24 (end of study)


Enrollment: 544
Study Start Date: February 2013
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omecamtiv mecarbil Drug: Omecamtiv mecarbil
Oral omecamtiv mecarbil dose of 25-mg BID for 7 days
Other Name: AMG 423
Drug: Omecamtiv mecarbil
Oral omecamtiv mecardbil dose of 50-mg BID for 7 days.
Other Name: AMG 423
Drug: Omecamtiv Mecarbil
Oral omecamtiv mecarbil dose of 25-mg BID for 20 weeks.
Other Name: AMG 423
Drug: Omecamtiv Mecarbil
Oral omecamtiv mecarbil dose of 25 mg BID for 8 weeks followed by 50-mg BID for 12 weeks
Other Name: AMG 423
Placebo Comparator: Placebo Drug: Placebo
Placebo

Detailed Description:

Omecamtiv mecarbil (AMG 423, CK-1827452) is a novel small molecule that increases cardiac contractility by selectively and directly activating the enzymatic domain of cardiac myosin heavy chain, the force-generating motor protein of the cardiac sarcomere. This is a randomized, placebo-controlled, multicenter, phase 2 study, consisting of a dose escalation phase to select 1 of 3 omecamtiv mecarbil oral formulations in 2 dose escalation cohorts, followed by an expansion phase to evaluate 20 weeks of administration of the selected omecamtiv mecarbil formulation at 2 target dose levels, compared with placebo.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of chronic HF, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening
  • Treated with stable, optimal pharmacological therapy for ≥ 4 weeks
  • History of left ventricular ejection fraction (LVEF) ≤ 40%
  • Elevated N-terminal fragment BNP (NT-proBNP)

Exclusion criteria:

  • Severe uncorrected valvular heart disease
  • Hospitalization within 30 days prior to enrollment
  • Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease
  • Acute Myocardial Infarction, Unstable angina or persistent angina at rest within 30 days prior to randomization
  • Systolic BP > 160 mmHg or < 90 mmHg or diastolic BP > 90 mmHg
  • TBL ≥ 2x ULN; AST or ALT ≥ 3x ULN
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01786512

  Hide Study Locations
Locations
United States, Alabama
Research Site
Moblie, Alabama, United States, 36608
United States, California
Research Site
Costa Mesa, California, United States, 92626
Research Site
Fresno, California, United States, 93721
Research Site
Inglewood, California, United States, 90301
Research Site
La Jolla, California, United States, 92037
Research Site
Los Angeles, California, United States, 90033
Research Site
Thousand Oaks, California, United States, 91360
Research Site
Tustin, California, United States, 92780
United States, Connecticut
Research Site
Danbury, Connecticut, United States, 06810
United States, Delaware
Research Site
Newark, Delaware, United States, 19718
United States, Florida
Research Site
Atlantis, Florida, United States, 33462
Research Site
Aventura, Florida, United States, 33180
Research Site
Clearwater, Florida, United States, 33756
Research Site
Miami, Florida, United States, 33136
Research Site
Tampa, Florida, United States, 33606
United States, Georgia
Research Site
Atlanta, Georgia, United States, 30322
Research Site
Macon, Georgia, United States, 31201
United States, Illinois
Research Site
Chicago, Illinois, United States, 60612
United States, Maine
Research Site
Auburn, Maine, United States, 04210
United States, Maryland
Research Site
Baltimore, Maryland, United States, 21201
United States, Michigan
Research Site
Detroit, Michigan, United States, 48202
Research Site
Petoskey, Michigan, United States, 49770
United States, Minnesota
Research Site
Minneapolis, Minnesota, United States, 55415
Research Site
Minneapolis, Minnesota, United States, 55417
United States, Missouri
Research Site
St Louis, Missouri, United States, 63110
United States, Nevada
Research Site
Las Vegas, Nevada, United States, 89128
United States, New York
Research Site
Bronx, New York, United States, 10467
Research Site
Cortlandt Manor, New York, United States, 10567
United States, North Carolina
Research Site
Chapel Hill, North Carolina, United States, 27599
Research Site
Durham, North Carolina, United States, 27705
United States, Oklahoma
Research Site
Oklahoma City, Oklahoma, United States, 73120
United States, Oregon
Research Site
Portland, Oregon, United States, 97239
United States, South Carolina
Research Site
Greenville, South Carolina, United States, 29605
United States, Tennessee
Research Site
Nashville, Tennessee, United States, 37232-8802
Research Site
Tullahoma, Tennessee, United States, 37388
United States, Texas
Research Site
Houston, Texas, United States, 77030
United States, Washington
Research Site
Seattle, Washington, United States, 98195
United States, Wisconsin
Research Site
Madison, Wisconsin, United States, 53792
Australia, New South Wales
Research Site
Darlinghurst, New South Wales, Australia, 2010
Australia, Western Australia
Research Site
Nedlands, Western Australia, Australia, 6009
Belgium
Research Site
Antwerpen, Belgium, 2020
Research Site
Bonheiden, Belgium, 2820
Research Site
Gent, Belgium, 9000
Research Site
Ieper, Belgium, 8900
Research Site
Liege, Belgium, 4000
Bulgaria
Research Site
Kazanlak, Bulgaria, 6100
Research Site
Pazardzhik, Bulgaria, 4700
Research Site
Plovdiv, Bulgaria, 4002
Research Site
Sandanski, Bulgaria, 2800
Research Site
Sliven, Bulgaria, 8800
Research Site
Smolyan, Bulgaria, 4400
Research Site
Sofia, Bulgaria, 1527
Canada, Alberta
Research Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, Manitoba
Research Site
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, Newfoundland and Labrador
Research Site
St. Johns, Newfoundland and Labrador, Canada, A1B 3V6
Canada, Nova Scotia
Research Site
Halifax, Nova Scotia, Canada, B3H 3A7
Canada, Ontario
Research Site
Ottawa, Ontario, Canada, K1Y 4W7
Canada, Quebec
Research Site
Montreal, Quebec, Canada, H3G 1A4
Research Site
Québec, Quebec, Canada, G1V 4G5
Research Site
Sherbrooke, Quebec, Canada, J1G 2E8
Research Site
Trois Rivieres, Quebec, Canada, G8T 7A1
Czech Republic
Research Site
Brno, Czech Republic, 625 00
Research Site
Brno, Czech Republic, 636 00
Research Site
Olomouc, Czech Republic, 771 11
Research Site
Praha 2, Czech Republic, 128 08
Research Site
Praha 4, Czech Republic, 140 21
Research Site
Svitavy, Czech Republic, 568 25
Research Site
Teplice, Czech Republic, 415 29
Germany
Research Site
Bad Krozingen, Germany, 79189
Research Site
Bad Nauheim, Germany, 61231
Research Site
Berlin, Germany, 13353
Research Site
Dortmund, Germany, 44137
Research Site
Greifswald, Germany, 17475
Hungary
Research Site
Budapest, Hungary, 1135
Research Site
Budapest, Hungary, 1125
Research Site
Budapest, Hungary, 1027
Research Site
Jaszbereny, Hungary, 5100
Research Site
Zalaegerszeg, Hungary, 8900
Italy
Research Site
Brescia, Italy, 25125
Research Site
Pavia, Italy, 27100
Research Site
Verona, Italy, 37134
Lithuania
Research Site
Kaunas, Lithuania, 50009
Research Site
Vilnius, Lithuania, 08661
Netherlands
Research Site
Amersfoort, Netherlands, 3813 TZ
Research Site
Groningen, Netherlands, 9713 GZ
Research Site
Utrecht, Netherlands, 3584 CX
Poland
Research Site
Bialystok, Poland, 15-276
Research Site
Klodzko, Poland, 57-300
Research Site
Krakow, Poland, 31-501
Research Site
Krakow, Poland, 31-202
Research Site
Lublin, Poland, 20-954
Research Site
Ruda Slaska, Poland, 41-703
Research Site
Warszawa, Poland, 04-256
Research Site
Wroclaw, Poland, 50-981
United Kingdom
Research Site
Dudley, United Kingdom, DY1 2HQ
Research Site
Dundee, United Kingdom, DD1 9SY
Research Site
Glasgow, United Kingdom, G11 6NT
Research Site
Harrow, United Kingdom, HA1 3UJ
Research Site
Leicester, United Kingdom, LE3 9QP
Research Site
Liverpool, United Kingdom, L14 3PE
Research Site
London, United Kingdom, EC1M 6BQ
Sponsors and Collaborators
Amgen
Cytokinetics
Investigators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided

Responsible Party: Amgen
ClinicalTrials.gov Identifier: NCT01786512     History of Changes
Other Study ID Numbers: 20110151
Study First Received: January 18, 2013
Last Updated: April 3, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Amgen:
Pharmacokinetics
Omecamtiv mecarbil
AMG 423
Double-blind
Randomized
Placebo-controlled
Oral forumlation
CK-1827452
Cardiac myosin activator

Additional relevant MeSH terms:
Heart Failure
Ventricular Dysfunction, Left
Cardiovascular Diseases
Heart Diseases
Ventricular Dysfunction

ClinicalTrials.gov processed this record on September 01, 2015